Topics, Trends & Updates

October 2026

View as web page

YouTube  Facebook  Linkedin  Instagram

Updated: Rapid ART Initiation

The Rapid ART Initiation guideline was developed by author Dr. Asa E. Radix and the Medical Care Criteria Committee to encourage rapid ART initiation—ideally on the same day or within 72 hours—in adults newly diagnosed with HIV.


Quick Links:

September 2026 Updates | Full Guideline | Printable PDF

Updated: Prevention and Management of Human Papillomavirus Infection in Adults With HIV

The Prevention and Management of Human Papillomavirus Infection in Adults With HIV guideline was developed by authors Dr. Nili Gujadhur, Dr. Meera Shah, and the Medical Care Criteria Committee to inform clinicians about HPV prevention, screening, presentation, diagnosis, and treatment in adults with HIV.


Quick Links:

October 2026 Updates| Full Guideline | Printable PDF

Save the Date: PrEP Aware Week 2026


Learn more at prepforsex.org

Hot Topics


See all Hot Topics

Don't Miss

Updated Guideline:
HIV Testing


Full Guideline | Printable PDF

Updated Guideline:
Treatment of Substance Use (Including Alcohol and Tobacco) During Pregnancy


Full Guideline | Printable PDF

Viremic—Cases in HIV Podcast

Join Hosts Eileen Scully and Christopher Hoffmann as they present cases, explore quandaries in adult HIV care, and discuss key evidence and guidelines that inform clinical decision-making.



New Episodes

Case 29. U=U: Living a New Normal: A 48-year-old man with HIV that is well-controlled on dolutegravir/lamivudine has met someone and they are starting to date. His partner is HIV-seronegative, and they have not yet been sexually active. Listen as Eileen Scully and Chris Hoffmann of Johns Hopkins discuss the importance of normalizing sexuality in patients with HIV and strategies for counseling patients that “undetectable=untransmittable (U=U).” Listen Now

Case 30. Problem Solving with New ARVs: A 43-year-old man with HIV is virally suppressed on Odefsey. He started Biktarvy 5 years ago but was switched because of headaches. He recently developed worsening kidney function. Listen as Chris Hoffmann of Johns Hopkins and guest Tony Urbina, from the Icahn School of Medicine at Mount Sinai, discuss switching this patient to a newly or soon-to-be approved antiretroviral medication. Listen Now

We’re open to suggestions! To submit a clinical topic for a Viremic case discussion, email us at viremicpodcast@jh.edu.

Conversations With CEI Podcast

Anabolic Androgenic Steroids: Is “The Cycle” Addictive? Anabolic androgenic steroids (AAS) are synthetic versions of testosterone, and like naturally produced testosterone, they can increase male sex characteristics and help build muscle. They are prescribed for low testosterone, delayed puberty, and muscle loss from severe illness, among other things. But AAS are also used regularly—particularly among gay, bisexual, and queer men—without a prescription to gain muscle and improve physical appearance. The health impact of use varies from injection-site infection to sexual dysfunction and high blood pressure, and many people who use AAS have developed creative ways to mitigate risk. Today’s episode will introduce AAS as performance-enhancing drugs and provide harm reduction strategies that clinicians can employ to mitigate risks associated with their use. Listen Now


AIDS 2026 in Rio: What Came Out of the 26th International AIDS Conference: AIDS 2026, the 26th International AIDS Conference, was held on July 26-31 in Rio. In this episode, Dr. Antonio E. Urbina, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, summarizes the clinical highlights from AIDS 2026, focusing on new HIV treatments and prevention strategies. Listen Now

Upcoming Training, Education, and Events

CEI:



See all


General:



See all

 

Are You a Subscriber?



If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program Topics, Trends, and Updates newsletter every month and stay current with new and updated guidelines. We send 1 email per month and do not share our mailing list.

Comments? Questions? Suggestions?


Email us: aiguidelines@jhmi.edu. 

We'll get back to you as quickly as possible.


Note that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice.